← Leaderboards
Gustavo Henrique Boff Maegawa
Columbia University Health Sciences
$4,263,337
Attributed
$4,263,337
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,263,337 · 7
By mechanism
R01$2,345,167 · 2
R61$766,453 · 1
R21$620,438 · 2
R33$451,494 · 1
R03$79,785 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Lorraine N Clark$7,054,136
Others in their field
Top investigators on “Lysosomal Storage Diseases”
- John H Wolfe · Children'S Hospital Of Philadelphia$28,073,185
- Ronald G Crystal · Weill Medical College Of Cornell Univ$16,870,313
- Stuart A Kornfeld · Washington University$16,342,633
- Patricia I Dickson · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center$9,370,497
- Nancy M. Dahms · Medical College Of Wisconsin$9,170,286
- Sean Ekins · Genego, Inc.$9,102,826
Research focus
Lysosomal Storage DiseasesCellsSmall MoleculePreventNeurologicBlood - Brain Barrier AnatomyPositioning AttributeGalactosylceramidaseResourcesAffectTherapeutic AgentsPsychosineHigh Throughput ScreeningInstitutionGloboid Cell LeukodystrophyOligodendrogliaHematopoietic Stem Cell TransplantationSphingolipidsIn VivoMouse ModelBrainBaseProteinsInherited
Grant awards (15)
A Novel Molecular Neutralization Strategy for Cytotoxic Sphingolipid in a Neurogenetic Disorder$539,304
R01 · FY2025 · NS · contact PI
A Novel Molecular Neutralization Strategy for Cytotoxic Sphingolipid in a Neurogenetic Disorder$622,404
R01 · FY2024 · NS · contact PI
Characterization of Small Molecule Therapeutic Agents for a Lysosomal Leukodystrophy$451,494
R33 · FY2024 · NS · contact PI
Characterization of Small Molecule Therapeutic Agents for a Lysosomal Leukodystrophy$613,688
R61 · FY2021 · NS · contact PI
Characterization of Small Molecule Therapeutic Agents for a Lysosomal Leukodystrophy$152,765
R61 · FY2021 · NS · contact PI
Exososomal CNS-Delivery of Therapies for a Lysosomal Disorder$313,301
R21 · FY2019 · NS · contact PI
Exososomal CNS-Delivery of Therapies for a Lysosomal Disorder$102,137
R21 · FY2019 · NS · contact PI
Development of a HTS Assay for a Neurological Lysosomal Disease$311,828
R01 · FY2015 · NS · contact PI
Development of a HTS Assay for a Neurological Lysosomal Disease$74,198
R01 · FY2015 · NS · contact PI
Development of a HTS Assay for a Neurological Lysosomal Disease$384,989
R01 · FY2014 · NS · contact PI
Development of a HTS Assay for a Neurological Lysosomal Disease$412,444
R01 · FY2013 · NS · contact PI
A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase$39,285
R03 · FY2013 · MH · contact PI
A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase$40,500
R03 · FY2012 · MH · contact PI
A HTS assay to identify molecular probes for arylsulfatase A$41,000
R21 · FY2011 · NS · contact PI
A HTS assay to identify molecular probes for arylsulfatase A$164,000
R21 · FY2010 · NS · contact PI